Neurocrine Biosciences, Inc.
NBIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.49B
Close$
$491.16
210.2% upside
Current Fair Value
210.2% upsideUndervalued by 210.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.49 Billion |
|---|---|
| Enterprise Value | $15.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.81 |
| Beta | 0.39 |
| Outstanding Shares | 101,000,000 |
Return
| Return on Equity | 17.68% |
|---|---|
| Return on Assets | 13.16% |
| Return on Invested Capital | 17.56% |
Valuation & Multiples
| P/E Ratio | 21.85 |
|---|---|
| PEG | 63.66 |
| Price to Sales | 4.8 |
| Price to Book Ratio | 4.06 |
| Enterprise Value to Revenue | 4.71 |
| Enterprise Value to EBIT | 20.18 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$1.65
Average shareholder expectationRevenue Estimate
$891.16 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$2.59
Average shareholder expectationRevenue Estimate
$1.04 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0323▼ 101.61% |
|---|---|
| Total Calls | 408,600▲ 99.90% |
| Total Puts | 421,800▲ 0.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 123.81%▲ 24.32% |
|---|---|
| Total Invested | $17.27B▲ 31.34% |
| Investors Holding | 791▲ 74.00% |
ESG Score
No data
About Neurocrine Biosciences, Inc.
CEO: Kevin Gorman